Development of an Evidence-Based List of Non-Antineoplastic Vesicants: 2024 Update.

Infiltration of a vesicant, called extravasation, can result in severe patient injuries. Recognition of vesicants and their relative risk of injury is essential to extravasation prevention, early recognition, and appropriate treatment. In this article, the Vesicant Task Force (VTF) updates the previously published Infusion Nurses Society (INS) vesicant list from 2017. The 2024 INS list diverges from earlier vesicant lists, such as the 2017 VTF list, by adopting a risk stratification approach based upon documented patient outcomes, in contrast to the reliance on expert consensus or only surrogate risk indicators, such as pH and osmolarity. The methodology used to create the updated list is explained, and the criteria for high- and moderate-risk vesicants and cautionary vesicants are defined.
Competing Interests: Conflicts of interest:Barb Nickel is on the Advisory Board for Baxter Healthcare; Lisa Gorski receives advisory and speaking honoraria from BD Medical and 3M (Solventum), speaking honoraria from Greiner, and holds stock in IvWatch; Lynn Hadaway was a consultant and speaker for BD Medical and B Braun Medical, and was a consultant for Atrion, AccuVein, and 3M (Solventum). These relevant financial relationships have been mitigated through peer review. There are no other relevant financial relationships for the authors or planners.
(Copyright © 2024 Infusion Nurses Society.)